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bFGF = basic fibroblast growth factor; EPC = endothelial progenitor cell; HIF = hypoxia-inducible factor; HIF-1α = hypoxia-inducible factor 1α;
HSC = hematopoietic stem cell; MMP = matrix metalloproteinase; MMTV = mouse mammary tumor virus; PDGF = platelet-derived growth factor;
VEGF = vascular endothelial growth factor; VEGFR = VEGF receptor; VHL = von Hippel-Lindau protein.
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Introduction
Like most solid tumors, breast cancers require new blood
vessel growth (neovascularization) if they are to grow
beyond a few millimeters in diameter [1]. The new vessels
not only help to meet the growing metabolic demands of
the tumor by supplying additional nutrients, but also
provide potential routes for tumor dissemination and
metastasis.
In breast cancers, tumor-induced angiogenesis is first
evident at the pre-invasive stage of high-grade ductal car-
cinoma  in situ. In this instance, a characteristic rim of
microvessels is formed around the ducts that are filled
with proliferating epithelial cells [2]. As the tumor contin-
ues to progress, so does the degree of neovascularization.
Not surprisingly, poor breast cancer prognosis has been
shown to correlate with increasing microvascular density
or production and with factors that stimulate new vessel
growth [3,4]. Accordingly, an extensive body of research
has focused on identifying the factors in the tumor
microenvironment that promote and support angiogenesis,
with the hope of limiting neovascularization and ultimately
tumor growth and metastasis. Moreover, anti-angiogenic
therapy is particularly attractive, because, unlike the tumor
cells, which are genetically unstable and can rapidly
acquire resistance to many therapeutic agents, the normal
vascular endothelium does not harbor mutations that
would facilitate acquisition of drug resistance. Both
strands of research are reviewed in this article.
The angiogenic cycle
In normal, quiescent capillaries, the endothelial cells are in
contact with a laminin-rich basement membrane and a
1- to 2-cell-thick layer of supporting pericytes. During
angiogenesis, the connections between the adjacent peri-
cytes must be weakened and the surrounding basement
membrane must be degraded. Endothelial cells re-enter
the cell cycle and invade the surrounding stromal matrix;
this invasion is facilitated by the integrin adhesion recep-
tors [5]. The endothelial cells begin to resynthesize a
Review
Breast cancer-induced angiogenesis: multiple mechanisms
and the role of the microenvironment
Nancy Boudreau1 and Connie Myers2
1Department of Surgery, University of California San Francisco, San Francisco, CA, USA
2Life Sciences Division, Lawrence Berkeley Laboratory, Berkely, CA, USA
Corresponding author: Nancy Boudreau (e-mail: nanycjb@itsa.ucsf.edu)
Published: 10 March 2003
Breast Cancer Res 2003, 5:140-146 (DOI 10.1186/bcr589)
© 2003 BioMed Central Ltd (Print ISSN 1465-5411; Online ISSN 1465-542X)
Abstract
Growth and progression of breast cancers are accompanied by increased neovascularization
(angiogenesis). A variety of factors, including hypoxia and genetic changes in the tumor cells,
contribute to increased production of angiogenic factors. Furthermore, cells within the activated tumor
stroma also contribute to the increase in production of vascular endothelial growth factor and other
angiogenic factors, including basic fibroblast growth factor and platelet-derived growth factor. The
contribution of the microenvironment to tumor-induced angiogenesis is underscored by findings that
breast tumors implanted into different tissue sites show marked differences in the extent and nature of
the angiogenic response. These findings have important implications for designing anti-angiogenic
therapies.
Keywords: angiogenesis, hypoxia-inducible factor 1α (HIF-1α), integrins, vascular endothelial growth factor
(VEGF)141
Available online http://breast-cancer-research.com/content/5/3/140
basement membrane, which promotes their acquisition of
capillary-like morphology and assists in withdrawal from
the cell cycle [6]. Pericytes are subsequently recruited to
the newly formed capillaries to help stabilize the maturing
vessels. In the tumor microenvironment, chronic exposure
to angiogenic factors that either support proteolysis of the
basement membrane and/or antagonize endothelial–peri-
cyte interactions results in creation of a relatively unstable,
highly permeable network of vessels which do not fully
mature, but nonetheless are capable of supplying nutrients
to meet the increasing metabolic demands of the tumor. In
fact, the increased permeability of these vessels is often
considered to facilitate extravasation and ultimately metas-
tasis of the tumor cells.
Factors that promote angiogenesis
Hypoxia
One of the features within the tumor microenvironment
that has long been suspected to act as a potent angio-
genic stimulus is hypoxia. The low tissue oxygen tension
arises from masses of tightly packed, rapidly growing cells
that lack access to an adequate supply of nutrients. Signif-
icant progress has been made in recent years toward
understanding the biochemical and molecular responses
to hypoxia and how the tissue senses the low oxygen
tension. Most notably has been the discovery of the
hypoxia-inducible factor (HIF), a heterodimeric transcrip-
tion factor consisting of the hypoxic response factor
(HIF-1α) and the constitutively expressed aryl hydrocar-
bon receptor nuclear translocator (ARNT or HIF-1β) [7].
Under oxygenated conditions, HIF-1α is bound to von
Hippel–Lindau (VHL) protein, which leads to ubiquitination
and rapid degradation of HIF-1α. In contrast, in hypoxic
conditions, this factor is stabilized: it cannot interact with
VHL protein, because prolyl hydroxylase, an enzyme that
normally modifies HIF-1α to promote its interactions with
VHL protein, is not active in hypoxic conditions [8]. Thus,
prolyl hydroxylase has been suggested to serve as the
oxygen sensor.
Strong evidence shows that HIF-1α plays a significant role
in experimental tumor growth and tumor-associated angio-
genesis; mice deficient in this factor have markedly
reduced angiogenic responses [9,10]. In humans, HIF-1α
is overexpressed in ductal carcinomas but not in benign
tumors, which lack extensive angiogenesis [11]. In the
hypoxic tumor microenvironment, stabilized HIF-1α directly
induces expression of many proangiogenic mediators,
most notably vascular endothelial growth factor (VEGF),
as well as one of its receptors, VEGF receptor 1
(VEGFR1) [12,13].
Vascular endothelial growth factor
As its name implies, VEGF is a potent and selective
endothelial mitogen that can induce a rapid and complete
angiogenic response. VEGF consists of a family of related
glycoproteins (VEGF-A, -B, -C and -D) identified by homol-
ogy with VEGF (VEGF-A), which has been the most exten-
sively studied and has been implicated in tumor-induced
angiogenesis. VEGF-C and -D primarily influence lym-
phatic endothelium [14].
VEGF is produced and secreted by a number of normal
cell types and its expression is markedly increased in tumor
cells, including a variety of breast tumors, and is also highly
upregulated in reactive breast tumor stromal cells [15].
However, in contrast to other cytokines produced by tumor
cells, VEGF acts almost exclusively on endothelial cells,
since expression of the major VEGF receptor, VEGFR2, is
restricted to such cells. Thus, interfering with VEGF or
VEGFR2 provides a means to selectively target tumor
endothelium. In contrast, VEGFR1 is expressed by
endothelial cells as well as monocytes and macrophages
and until recently the role of VEGFR1 has been more enig-
matic [16,17]. Once bound to its receptor, VEGF initiates
an intracellular signaling cascade that leads to changes in
expression of the gene that promote endothelial cell migra-
tion and proliferation. In addition, VEGF not only is a potent
mitogen for endothelium, but also produces a marked
increase in permeability of capillaries [18], and perhaps it is
not surprising that a major distinguishing feature between
normal capillaries and tumor vessels is the leakiness of the
tumor vessels [18,19].
VEGF and breast tumor angiogenesis
As mentioned already, angiogenesis induced by breast
tumors has been linked to an increased production of
VEGF both by the tumor cells and by cells within the
tumor stroma [15]. Furthermore, an increase in expression
of VEGFR2 has also been noted in the adjacent breast
tumor endothelial cells. In fact, an increased expression of
VEGF corresponds with the earliest visible breast-tumor-
induced angiogenesis that is evident in pre-invasive high-
grade ductal carcinoma in situ [20].
A number of factors are believed to contribute to the
increased expression of VEGF in the breast tumor envi-
ronment. Clearly, hypoxia and HIF-1α play a prominent
role [11].  The findings that there are higher levels of
VEGF expression in premenopausal than in post-
menopausal women suggested that steroid hormones
may also increase VEGF expression. [21]. It has long
been recognized that estradiol is angiogenic, and evi-
dence suggests that estrogen effects may be mediated
by induction of VEGF [22]. For example, VEGF is upregu-
lated by estrogens and decreased by progestins in
certain breast cancer cell lines [23,24]. More recently,
the estrogen receptor inhibitor tamoxifen was shown to
suppress VEGF transcription [25,26]. However, it
remains to be established whether estrogen receptor
expression directly correlates with VEGF expression and
vascular density.142
Breast Cancer Research    Vol 5 No 3 Boudreau and Myers
Other changes within the tumor environment also posi-
tively influence VEGF production. For example, many
tumor cells, including human breast tumors, often secrete
high levels of matrix metalloproteinases. One member of
this family that has received considerable attention is
matrix metalloproteinase (MMP)-9, which is released by
tumor cells and is expressed at high levels in human
breast tumors [27]. MMP-9 was shown to be capable of
proteolyzing the adjacent extracellular matrix and releasing
sequestered VEGF, thus increasing its bioavailability [28].
Another important change in breast tumors is expression
of  HER2.  HER2 is a member of the epidermal growth
factor receptor family of tyrosine kinase receptors
encoded by the ERB2 gene and signals in the absence of
any known ligand.  Moreover,  HER2  overexpression or
heregulin stimulation leads to an increase in VEGF mRNA
[29,30], while treatment of breast cancers with a neutraliz-
ing antibody against HER2 results in a dose-dependent
inhibition of VEGF production [31]. Furthermore, HER2
was shown to increase the rate of HIF-1α protein synthe-
sis, not by preventing degradation as is observed during
hypoxia, but in a novel, rapamycin-dependent manner [32].
Other changes in epithelial gene expression associated
with increased tumorigenicity can also enhance VEGF
production. The α6β4 integrin, which normally promotes
interactions of breast epithelium with basement mem-
brane, is increased in breast tumor cells and is also mislo-
calized and consequently promotes invasiveness of tumor
cells. Recent studies show that α6β4 signaling leads to an
inactivation of eIF-4E, a translational repressor, which in
turn increases VEGF translation and ultimately increases
survival of these tumor cells [33]. Similar to the HER2-
mediated increases in HIF-1α and VEGF, the α6β4 signal-
ing pathway that promotes translation of VEGF also
converges on a rapamycin-sensitive pathway. Also impor-
tantly, the increase in VEGF production by the tumor cells
has been suggested to function in an autocrine manner to
directly promote epithelial cell survival [33].
Host microenvironment and angiogenesis
It has long been suspected that the tumor microenviron-
ment affects the angiogenic response of the tumor cells.
In studies of the degree of vascularity of primary breast
tumors and their axiliary lymph node metastasis, marked
variations were found in the level of vascularity and angio-
genesis in individual tumors and their metastatic clones
within the same patient, raising the possibility that different
microenvironments affected the tumor’s angiogenic
response [34]. In more recent studies, the same estrogen-
dependent breast tumor line implanted either into the
mammary gland fat pad or into the cranium displayed dif-
ferent angiogenic responses. Tumors implanted in the
mammary fat pad displayed increased expression of VEGF
and increased vascular permeability. The adjacent
endothelial cells also displayed greater expression of
VEGFR1 and VEGFR2 than endothelial cells adjacent to
tumors in the cranial site (a common metastatic route)
[35]. However, in the cranial tumors there was an overall
increase in angiogenesis.
These results clearly show that the tumor microenviron-
ment is a major determinant of the angiogenic response.
They also indicate that experimental models designed to
study breast tumor angiogenesis should carefully consider
the site of tumor implantation. To date, most models of
breast cancer angiogenesis have relied on subcutaneous
injection into mice or implantation of tumors in human skin
grafted onto immunocompromised mice, the latter provid-
ing the benefit that the response of human vessels can be
evaluated. One recent study showed, in fact, that when a
mammary carcinoma cell line derived from mice infected
with the mouse mammary tumor virus (MMTV) was subcu-
taneously injected into syngeneic mice, the resulting tumor
vasculature was highly sensitive to inhibitors including
interleukin 12 and interferon gamma. In contrast, in tumors
that developed naturally in the mammary gland of mice
carrying the MMTV oncogene, the resulting tumor vascula-
ture did not respond to the same agents and the vessels
associated with the tumor appeared to be relatively more
mature than those developing in the subcutaneous envi-
ronment [36]. Again, these findings emphasize the need to
consider the appropriate environment when evaluating
breast-cancer-induced angiogenesis. In addition to the
MMTV mice, a variety of other transgenic models is cur-
rently available that would facilitate direct evaluation of
tumor-induced angiogenesis in the mammary gland [37].
In many of these mouse models, breast cancers can be
selectively induced by using mammary-gland-specific pro-
moters to drive expression of a variety of tumor-promoting
genes.
Anti-VEGF treatment and breast tumor
angiogenesis
Given the large body of work implicating VEGF and its
receptors as prime culprits in facilitating breast tumor angio-
genesis, several therapies designed to counteract the
effects of VEGF are currently undergoing advanced clinical
trials. Notably, soluble antagonists of the VEGF receptors,
specific tyrosine kinase inhibitors (Su5416) and monoclonal
antibodies against VEGF (bevacizumab, avastin) have been
developed to target the tumor endothelium specifically.
Recent reports, however, indicate that although avastin
showed initial promise in combating breast tumor angiogen-
esis, follow-up studies showed that the long-term prognosis
in treated patients was not improved.
The underlying reasons for the lack of long-term effective-
ness using anti-VEGF or perhaps other anti-angiogenic
therapies are not known, yet it raises several potentially
informative issues regarding sustained angiogenic143
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responses by tumor cells. First of all, no evidence has
been provided to suggest whether endothelial cells even-
tually acquire resistance to these or other anti-angiogenic
treatments. Secondly, given that the tumor microenviron-
ment retains many of the features that enhance VEGF
expression, such as hypoxia, it is unlikely that tumor cells
simply stop producing this factor. However, it is possible
that tumors may evolve in a manner such that they no
longer require angiogenesis or VEGF for survival. Recent
studies also showed that many tumors that have mutations
in the p53 gene have consequently adapted to chronic
hypoxic environments and in fact are not significantly
affected by anti-angiogenic therapies [38]. Thus, failure of
long-term anti-VEGF treatment to improve patient survival
might indicate that certain tumors have acquired p53
mutations and thus are no longer as susceptible to death
due to a limited blood supply. Since many breast tumors
and commonly used breast cancer cell lines, such as
MDA231, have nonfunctional p53 [4], these findings
should be taken into consideration when designing
studies to evaluate breast tumor angiogenesis.
Another possible explanation for the lack of long-term
effects of anti-VEGF therapy in breast cancer may be that
the genetic instability of tumor cells allows them to acquire
the capability of expressing other angiogenic factors to
supplant their dependency on VEGF. For example, in addi-
tion to expressing high levels of VEGF, many solid tumors,
including breast tumors, secrete high levels of other angio-
genic factors, including basic fibroblast growth factor
(bFGF) and platelet-derived growth factor (PDGF) [39]. In
fact, studies have shown that although VEGF is required
for the initial growth of human breast tumor carcinoma
cells, after the tumor had reached a certain size, they were
no longer dependent on VEGF but instead showed
increased expression of bFGF [40]. Given a tumor’s notori-
ous ability to acquire resistance to a number of therapeutic
agents, it may well be that tumors change the profile of
angiogenic factors they produce in response to therapeutic
selection pressures. The major drawback to targeting
bFGF or PDGF receptors, however, is that these receptors
are expressed on cells other than the endothelium, a fact
which may increase the potential for adverse side effects.
Integrins and angiogenesis
Endothelial cells must also be enabled to adhere to the
activated tumor stroma to effectively migrate and invade
adjacent tissue. Invasion and adhesion to the tumor
stroma requires an increase in the expression of special-
ized extracellular matrix receptors, the integrins, which reg-
ulate adhesion to and migration through extracellular
matrices [5]. To date, no endothelium-specific integrins
have been discovered, but there are several endothelial-
cell integrins that show a limited tissue distribution and,
more importantly, are not expressed on quiescent
endothelium but are upregulated in response to the tumor
microenvironment. One of these is αvβ3 integrin, which is
not expressed on resting quiescent endothelial cells but is
markedly upregulated in endothelial cells at sites of angio-
genesis, including wound repair and angiogenesis
induced in response to human breast tumor cells [41].
This integrin binds to fibrinogen, tenascin, fibronectin and
proteolyzed collagen, which are highly expressed in the
breast tumor stroma [15]. Binding to these ligands by αvβ3
allows endothelial cells to migrate into the adjacent
stroma, and blocking αvβ3 not only prevents endothelial
cell migration and angiogenesis but also leads to apopto-
sis of endothelial cells [5,41].
A humanized antibody against αvβ3 integrin has been
developed and is now entering clinical trials, but its effec-
tiveness in treating breast cancer remains to be estab-
lished. Nonetheless, the finding that αvβ3 is largely
restricted to angiogenic endothelium has provided an
additional strategy for targeting vascular endothelial cells
by coupling αvβ3-specific antibodies to nanoparticles
capable of delivering more generalized inhibitors of signal-
ing pathways activated during angiogenesis [42].
Earlier findings showed that the tumor microenvironment
is a critical determinant of the nature and extent of the
angiogenic response [35,36]. It is not clear how integrin
expression levels or the nature of the integrin heterodimers
expressed by the angiogenic endothelium correlates with
the different tumor environments.
Another integrin that is upregulated in angiogenic vessels
associated with human breast tumors is the fibronectin
receptor α5β1. Blocking this integrin with specific antibod-
ies can impair angiogenesis induced by bFGF but not
VEGF in the chick chorioallantoic membrane assay [43]. In
addition to α5β1, the collagen receptor α2β1 can also
mediate angiogenesis in response to VEGF [44].
It is possible that the specific integrin used for angiogene-
sis by a particular tumor type may be dictated by the
nature of the factors the tumor secretes or other proper-
ties of the tumor microenvironment. For example, although
α2β1 is upregulated by VEGF, αvβ3 and α5β1 are not, but
instead are induced by bFGF, tumor necrosis factor alpha
and other angiogenic cytokines [43–45]. Therefore if the
tumor changes its production of angiogenic factors, this
may also change the relative expression levels of various
integrins on the corresponding tumor endothelium. It
would therefore seem necessary to compare different
stages of tumors (VEGF-dependent vs other angiogenic
factors) in order to fully appreciate the types of integrins
that may contribute to tumor-induced angiogenesis.
Recent studies also showed that mice lacking both β3 and
β5 integrins could still undergo a significant degree of
angiogenesis in response to melanoma or Lewis lung car-144
cinoma tumors injected subcutaneously and showed a
normal angiogenic response to hypoxia, suggesting that
β3 or β5 integrins were not essential for tumor angiogene-
sis [46]. Again, it is not clear whether tumors that do not
rely on VEGF would do equally well in these mice, or
whether the same tumor would elicit strong angiogenic
responses in other microenvironments such as the brain or
mammary fat pad.
Proteolyzed fragments of extracellular matrix
as inhibitors of angiogenesis
In addition to their role in facilitating tumor invasion and
angiogenesis, matrix metalloproteinases have recently been
assigned a role in helping block tumor progression and
angiogenesis. One of the first naturally occurring inhibitors
of angiogenesis identified was angiostatin, a 38-kDa inter-
nal cleavage production of plasminogen, generated by
tumor cell MMP-2 [47]. Subsequently another naturally
occurring, potent inhibitor of angiogenesis, endostatin, was
discovered; it is a product of proteolyzed collagen XVIII
[48]. More recently, two groups have reported that various
proteolytic fragments of the basement membrane compo-
nent type IV collagen can inhibit angiogenesis [49,50].
One fragment, named tumstatin because of its ability to
impair tumor growth and angiogenesis, initially binds to
αvβ3 and subsequently leads to enhanced binding of
4EBP1 to eIF-4E to block protein translation through a
rapamycin-sensitive pathway. Moreover, this aspect of tum-
statin’s action was specific to endothelial cells [50]. In con-
trast, the collagen-XVIII fragment, endostatin, does not
influence protein synthesis in endothelial cells.
Recent studies, however, have shed light on the mecha-
nism of endostatin’s antiproliferative and anti-angiogenic
action. Endostatin can interfere with the Wnt signaling
pathway and block β-catenin/TCF-mediated transcription
of the cell cycle mediators cyclin D and c-Myc [51]. Not
clear, however, is the relative abundance of these
inhibitors in the tumor environment. Do dormant or less
aggressive tumors produce relatively more of these
inhibitory fragments or do different tumor microenviron-
ments also influence the levels produced? Since genera-
tion of inhibitory fragments requires matrix-degrading
proteinases, it is not clear whether the disappointing
results seen using protease inhibitors as antimetastastic
and anti-angiogenic agents is related to interfering with
the production of these inhibitory fragments.
Endothelial progenitor cells and tumor-
induced angiogenesis
One of the most exciting developments in the area of
tumor-induced angiogenesis is the finding that endothe-
lial progenitor cells (EPCs) can be recruited into the cir-
culation, become incorporated into new tumor-associated
vasculature and differentiate into endothelial cells [52].
Although endothelial-cell progenitors were initially iso-
lated from peripheral blood, EPCs originate from a renew-
ing population of hematopoietic stem cells (HSCs) resid-
ing in the bone marrow [53,54]. In an elegant series of
experiments, Lyden et al. [52] showed that deletion of the
mouse Id-1 and Id-3 genes, which encode transcription
factors, impaired the mobilization of HSCs. Furthermore,
inhibition of HSC and EPC mobilization prevented
xenografted tumors from inducing an initial angiogenic
response in these animals. However, when wild-type
HSCs were grafted into the marrow of the Id-1- and Id-3-
null mice, the tumors consequently produced a robust
angiogenic response and tumor growth was increased.
Thus, the tumors were capable of producing angiogenic
factors that mobilize and recruit HSCs to the areas of
neovascularization. Although the Id-null mice are heavily
dependent on recruitment of HSCs for establishing any
measurable tumor vasculature, it is not clear to what
extent the recruitment of HSCs contributes to tumor
angiogenesis in other settings.
Not surprisingly, VEGF and VEGFR2, expressed on
HSCs, are believed to be critical for maintenance, expan-
sion and recruitment of HSC populations, since mice
lacking VEGF or VEGFR2 are deficient in angiogenesis
as well as hematopoiesis [55]. Recent studies have
helped to establish an essential role for VEGFR1 in this
process. Specific inhibition of VEGFR1 blocked cycling
of HSCs as well as repopulation of the bone marrow after
suppression [17] and could also block tumor-induced
angiogenesis [16]. Furthermore, addition of placental
growth factor, a member of the VEGF family that acts
exclusively on VEGFR1, could restore hematopoiesis. A
corresponding increase in expression of MMP-9 leads to
proteolysis and release of c-kit ligand from the marrow
matrix, which in turn stimulates expansion of the HSC
population [56].
Although recruitment of EPCs into tumor vasculature has
so far been observed only in experimental models of tumor
angiogenesis, it is worth noting that studies in humans
have identified a renewable source of EPCs in bone
marrow, and circulating endothelial progenitor cells have
been detected in inflammatory breast cancers [54,57]. Fur-
thermore, human HSC progenitors transplanted into nude
mice can be recruited to the tumor vasculature [58]. There-
fore, the likelihood that EPC recruitment and incorporation
will emerge as an important component of tumor angiogen-
esis in human disease is strong. At the moment, however, it
is not clear whether selective inhibition of VEGFR1 to
block recruitment of these cells will also have a negative
effect on other aspects of bone marrow function.
Vascular mimicry
Another example of a tumor cell’s survival strategy in the
absence of classic angiogenesis is the phenomenon of vas-
cular mimicry, where bona fide capillaries are not present,
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yet conduits for the transport of nutrients are observed. A
controversial study [59] showed that certain nonvascular
tumors contained channels that were devoid of endothelial
cells but lined by tumor cells and displayed many properties
of a circulatory system. In this instance of vascular mimicry,
channels between tightly packed uveal melanoma cells
appear to express many of the genes normally associated
with endothelial cells. It is not clear whether there was evi-
dence of blood flow through the channels formed between
the uveal melanoma cells. Nonetheless, this finding raises
the interesting question of whether the ability to form a
pseudo-vasculature may be another example of an elaborate
survival strategy arising from heterogeneous, genetically
pliable tumors and present an additional complication for
conventional anti-angiogenic therapies.
The future of anti-angiogenic treatment and
breast cancer
Despite the variety of means that can be adopted by the
tumor cells to ensure an angiogenic response and despite
their ability to overcome the need for conventional angio-
genesis to survive, anti-angiogenic therapy still holds great
promise. In particular, agents that target both the growth of
breast tumor cells and their ability to produce angiogenic
factors, such as HER2-neutralizing antibodies, should prove
to be particularly effective. In addition, since tumor cells can
rapidly acquire resistance to many chemotherapeutic
agents, direct targeting of the vascular endothelium using
particles coupled to αvβ3 or VEGFR2 to deliver potent
inhibitors of essential signaling pathways also provides an
additional strategy to keep tumor growth and metastasis in
check. It will also be important to characterize the nature of
angiogenic factors produced by increasingly aggressive
tumors as well as consider means to combat the potential
recruitment of endothelial progenitor cells to sites of tumor
growth. By studying the angiogenic responses to tumors
generated within the breast microenvironment, it may be
possible to determine the relative contribution of each of
these factors and design the appropriate means to control
breast-tumor-induced angiogenesis.
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